http://www.medications.com/effect/view/39466 On January 13, 2009, the FDA released a Follow-up to their March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair). Included in this update is the following information: "Post-marketing reports of neuropsychiatric events